Basit öğe kaydını göster

dc.contributor.authorMelikoglu, Melike
dc.contributor.authorHatemi, Gulen
dc.contributor.authorOngen, Gul
dc.contributor.authorOzguler, Yesim
dc.contributor.authorSeyahi, Emire
dc.contributor.authorAtahan, Ersan
dc.contributor.authorBorekci, Sermin
dc.contributor.authorUgurlu, Serdal
dc.contributor.authorHamuryudan, Vedat
dc.date.accessioned2021-03-03T20:25:01Z
dc.date.available2021-03-03T20:25:01Z
dc.date.issued2016
dc.identifier.citationOzguler Y., Hatemi G., Ugurlu S., Seyahi E., Melikoglu M., Borekci S., Atahan E., Ongen G., Hamuryudan V., "Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy", RHEUMATOLOGY INTERNATIONAL, cilt.36, sa.12, ss.1719-1725, 2016
dc.identifier.issn0172-8172
dc.identifier.otherav_59bf7c68-c881-4fb7-83e0-e70bced61061
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/63138
dc.identifier.urihttps://doi.org/10.1007/s00296-016-3575-3
dc.description.abstractThe use of anti-TNF agents is associated with an increased risk of tuberculosis (TB) and anti-TNF agents are stopped when active TB develops. However, discontinuation of treatment can result in flare of the underlying disease. The charts of 22 patients who developed active TB among a cohort of 2754 patients using anti-TNF agents between 2001 and 2013 were reviewed retrospectively. Patients restarting biologics during further follow-up were identified. One patient with miliary TB died within 1 month. A biologic agent was restarted in 16 of the remaining 21 patients (76 %). The most frequently re-initiated biologic agent was etanercept (n = 6) followed by rituximab (n = 5) and interferon-alpha (n = 3). Biologic treatment was re-initiated during anti-TB treatment in four patients and after completing TB treatment in 12 patients. The median follow-up after restarting biologics was 53 (IQR: 40-75) months. TB re-occurred in one patient with Beh double dagger et's syndrome, who initially received etanercept due to severe sight-threatening uveitis at the third month of anti-TB treatment followed by canakinumab 15 months later along with methotrexate, cyclosporine and corticosteroids. After a second course of 9 months TB therapy this patient is currently stable on interferon-alpha for 33 months. Restarting of anti-TNF agents and other biologic agents, even during TB treatment, seems to be possible among patients who had previously developed TB under anti-TNF treatment. However, the risk of re-development of TB infection mandates careful follow-up.
dc.language.isoeng
dc.subjectİmmünoloji ve Romatoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleRe-initiation of biologics after the development of tuberculosis under anti-TNF therapy
dc.typeMakale
dc.relation.journalRHEUMATOLOGY INTERNATIONAL
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume36
dc.identifier.issue12
dc.identifier.startpage1719
dc.identifier.endpage1725
dc.contributor.firstauthorID61221


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster